Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance in newly diagnosed multiple myeloma
NCT02112175Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Apr 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02112175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112175.